No recommendations are made for or against specific<unk> –C or<unk> -HDL–C<unk>  for the 
primary prevention or secondary prevention of atherosclerotic cardiovascular disease (ASCVD) given the lack of evidence on titration of<unk> -lowering therapy to specific<unk> .
Blood cholesterol LDL and non-HDL treatment goals
High cholesterol primary prevention
High cholesterol secondary prevention
High density lipoprotein future or investigational therapies
Chronic stable angina treatment lipid management
High density lipoprotein medical therapy
Rosiglitazone detailed information
Diabetes primary prevention of cardiovascular events